Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Analyst Ratings for Ventrus Biosciences (VTUS)
Overall Rating: BUY Rating Trend: Up Avg. $ Target: $18.83 (+1062.6%)
2/12/2014 Cantor Fitzgerald Downgrade Hold
(Buy) 2.50
(6.00) 4.38 1.62 -63.01% Details
2/12/2014 William Blair Downgrade Market Perform
(Outperform) N/A
(10.00) 4.38 1.62 -63.01% Details
6/14/2012 Brean Capital New Coverage Buy
(N/A) 30.00
(N/A) 10.04 1.62 -83.86% Details
7/25/2011 Lazard Capital New Coverage Buy
(N/A) 24.00
(N/A) 11.89 1.62 -86.38% Details
7/25/2011 Leerink Swann New Coverage Outperform
(N/A) N/A
(N/A) 11.89 1.62 -86.38% Details
2/2/2011 Rodman & Renshaw New Coverage Market Outperform
(N/A) N/A
(N/A) 6.14 1.62 -73.62% Details
1/27/2011 National Securities New Coverage Buy
(N/A) N/A
(N/A) 6.41 1.62 -74.73% Details
http://www.streetinsider.com/rating_history.php?q=VTUS
Who owns Giga-tronics, Incorporated?
http://stockzoa.com/ticker/giga/
GigOptix Inc : GigOptix, Inc. and CPqD Announce Signing of Definitive Agreements to Incept BrPhotonics Produtos Optoeletrônicos LTDA., a New Joint Venture Company in Brazil
02/11/2014 | 04:35pm US/Eastern
GigOptix, Inc. and CPqD Announce Signing of Definitive Agreements to Incept BrPhotonics Produtos Optoeletrônicos LTDA., a New Joint Venture Company in Brazil
BrPhotonics is Set to Provide Advanced High-Speed Components for Optical Communications Utilizing Silicon Photonics (SiPh) and Thin Film Polymer on Silicon (TFPSTM) Technologies to Advance 100Gbps to 1Tbps Fiber-Optic Long Haul, Metro Links and Cloud-connectivity in CFP2 and CFP4 Applications
SAN JOSE, Calif.--(BUSINESS WIRE)--Feb. 11, 2014-- GigOptix, Inc. (NYSE MKT: GIG), a leading supplier of advanced high speed semiconductor components for use in long haul and metro telecom, Cloud connectivity, data centers, consumer electronics links and interactive applications, through optical and wireless communications networks, today jointly announced with CPqD, a leading Brazil-based research center organization focused on Information and communication technologies with solid activities on optical communications at systems and devices level, the signing of definitive agreements to incept a newly established joint venture company named BrPhotonics Produtos Optoeletrônicos LTDA. (BrP), headquartered in Campinas, Brazil.
Both partners will transfer into BrPhotonics their knowledge-base and intellectual property of current existing technologies, and will jointly work through the partnership to enhance, develop, and commercialize advanced products based on these technologies. GigOptix will transfer to Brazil its Thin Film Polymer on Silicon (TFPSTM) technology, inventory related to the TFPSTM platform, as well as the complete production line equipment currently residing at its Bothell, Washington, facility. CPqD will transfer to BrPhotonics its Silicon Photonics (SiPh) technology, optical packaging expertise and design and testing capabilities. In addition, CPqD will provide space for the BrPhotonics corporate headquarters and the funding for the BrPhotonics operations.
Business Structure
The ownership of BrPhotonics will be split between the companies, with CPqD controlling a 51% share and the remaining 49% controlled by GigOptix. BrPhotonics will be managed by a team that will be comprised of three Officers, and four Board of Directors. The Board of Directors of BrPhotonics will include two representatives from GigOptix and two representatives from CPqD, and will be initially chaired by GigOptix Chairman of the Board of Directors and Chief Executive Officer Dr. Avi Katz. BrPhotonics will launch operations immediately and will announce shortly the nominated executives and board members.
GigOptix will act as BrPhotonics' global exclusive sales and marketing agent for all its products, except in Brazil, where the sales will be done directly by BrPhotonics. BrPhotonics will enable GigOptix to extend its business footprint in Brazil through access to BrPhotonics' regional office and sales force.
BrPhotonics' headquarters will be located within the CPqD campus. Logistics of the transfer of equipment and IP to BrPhotonics facility will begin immediately. For sales inquiries please contact Sales@gigoptix.com or www.brphotonics.com.
"Today we are honored and delighted to announce the joint venture partnership between GigOptix and CPqD to form BrPhotonics," said Dr. Avi Katz, Chairman and Chief Executive Officer of GigOptix, Inc. "The creation of BrPhotonics is another innovative business strategy from GigOptix to gain access to advanced technologies and partner with some of the most highly skilled technical teams in the world. This latest agreement follows our long history of similar access to new technologies, including when GigOptix licensed the Silicon Germanium Millimeterwave Technology from IBM for E-band chipsets in June 2012, and several successful corporate acquisitions. More so, with the inception of BrPhotonics, GigOptix is setting a new and solid foothold in Brazil which is one of the fastest growing markets for our entire high-speed communications devices portfolio, as part of our global reach enhancement."
"CPqD is delighted to announce the creation of BrPhotonics as a strategic step to increase photonic companies' ecosystem in Brazil," said Mr. Helio Graciosa, CEO of CPqD. "BrPhotonics creation represents an opportunity to reach the market with the latest advances in integrated photonics developed at CPqD in last years, supported by Brazilian Government (Ministry of Communications/FUNTTEL and Ministry of Science, Technology and Innovation/FINEP). The complementary R&D activities between CPqD and GigOptix are key drivers to BrPhotonics roadmap and future products."
"This partnership leverages expertise from GigOptix and CPqD to bring small form factor Thin Film Polymer on Silicon (TFPSTM) modulation devices and Silicon Photonics (SiPh) based products to the market in the fastest and most efficient manner. CPqD brings a wealth of silicon photonics knowledge, device designs, optical device packaging, and world renowned systems capability to the partnership, and GigOptix reciprocates with our well-developed TFPSTM technology and our world-wide deep commercialization reach. GigOptix will continue to enhance our fabless, process-agnostic business model and to focus our efforts on the design and commercialization of semiconductor devices for high speed communication links. This enables information streaming, end-to-end, over the network from the content generator and into the end-user appliances," said Dr. Avi Katz.
"We are honored to sign the BrPhotonics joint venture partnership with GigOptix. BrPhotonics has been launched with a great technological capability with the advanced Thin Film Polymer on Silicon technology from GigOptix and Silicon Photonics technology from CPqD. We are also pleased with the strong support that we have received from the Brazilian government in the formation of BrPhotonics. The business plan for BrPhotonics that has been put together with CPqD and GigOptix represents a significant development opportunity for new optical components, reference platforms, and technologies," said Mr. Helio Graciosa.
Business Partnership
BrPhotonics' roadmap will include a 100Gbps DP-QPSK TOSA and ROSA for CFP2 form factor reference platforms with the integration of a TFPSTM modulator today. Future products are expected to include the development of a next generation 100Gbps to 1Tbps TOSA and ROSA for CFP4 form factor reference platforms utilizing Silicon Photonics components. The TFPSTM technology is an excellent zero-chirp medium for electro-optical modulation and capable of very high data rates in advanced linear and multi-level modulation systems. Silicon Photonics has many potential advantages including longer optical link distances, lower power and cost, and smaller form factors. These technology advantages may enable novel communications architectures and platforms to address capacity concerns with growing cloud services, entertainment on-demand, and big data processing.
In the January 2014 MarketsandMarkets report, Silicon Photonics Market by Products (Silicon Optical Interconnects & Wavelength Division Multiplexer Filters & Others), Applications (Telecommunication, Datacom, High Performance Computing & Others) & Geography - Analysis & Forecast (2013-2020), the Silicon Photonics global market revenue is estimated to grow from $88.66 million in 2013 to $410.78 million in 2020 at a CAGR of 24.5%. According to this market research report, this growth will be led by the telecom and datacom applications market for Silicon Photonics products. The report also projects that the Silicon Photonics applications in the high performance computing sector are expected to grow rapidly in the coming seven years with a CAGR of 48%.
BrPhotonics' products will utilize sophisticated TFPSTM and SiPh technologies to advance 100Gbps to 1Tbps fiber-optics long haul, metro links and cloud connectivity. BrPhotonics' unique portfolio of small form factor components will address CFP2 and CFP4 applications by enabling greater network capacity through superior linearization, multi-level modulation, and other advanced techniques.
Demonstration at OFC
BrPhotonics will showcase a 100Gbps TOSA for CFP2 reference design at OFC2014, scheduled for March 11-13, 2014, in San Francisco, Calif., at the GigOptix's Booth (Booth #1531).
About BrPhotonics Produtos Optoeletrônicos LTDA. (BrP)
BrPhotonicsis a leading provider of advanced high-speed devices for optical communications and integrated transceiver components that enable information streaming over communication networks. The products utilize sophisticated technologies such as Silicon Photonics (SiPh) and Thin Film Polymer on Silicon (TFPSTM) to advance the 100Gbps to 1Tbps fiber-optics long haul, metro links and cloud connectivity. BrPhotonics' unique portfolio of small form factor components addresses CFP2 and CFP4 applications by enabling a greater network capacity through superior linearization, multi-level modulation, and other advanced techniques.
About CPqD
CPqD is an independent institution, focused on innovation in information and communication technologies (ICTs). The solutions of the contributing authors are used by businesses and institutions in Brazil and internationally in sectors such as telecommunications, utilities, financial, industrial, public administration and defense and security. Operating for 37 years, CPqD has more than 1,300 highly trained professionals, recognized for their creativity and commitment to high quality standards. Today CPqD has the largest program of R&D in Latin America, partially supported by Brazilians R&D Funds, in its area of operation and aims to contribute to Brazil's competitiveness and digital inclusion society leading to market product technologies, mission-critical systems and technology services and consulting that benefit large and small businesses, increasing efficiency, and leveraging these business entrepreneurship in Brazil.
About GigOptix, Inc.
GigOptix is a leading fabless supplier of high speed semiconductor components that enable end-to-end information streaming over optical and wireless networks. The products address long haul and metro telecom applications as well as emerging high-growth opportunities for Cloud and data centers connectivity, and interactive applications for consumer electronics. GigOptix offers a unique broad portfolio of Drivers and TIAs for 40Gbps, 100Gbps and 400Gbps fiber-optic telecommunications and data-communications networks, and high performance MMIC solutions that enable next generation wireless microwave systems up to 90GHz. GigOptix also offers a wide range of digital and mixed-signal ASIC solutions and enables product lifetime extension through its GigOptixSunset Rescue Program.
Forward-Looking Statements
This press release contains forward-looking statements of GigOptix within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including the acts to be conducted to continue with the formation and operation of BrPhotonics and the bringing of products to market with full documentation. Such statements contain words such as "will," and "expect," or the negative thereof or comparable terminology, and include (without limitation) statements regarding the plans for BrPhotonics and its relationship with GigOptix. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and "bring to market" plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to move product sales to production levels, the ability to compete for client design-in opportunities, the ability to cross-sell to new clients and to diversify, the success of product sales in new markets or of recently produced product offerings, including bundled product solutions, and the ability of the partners to BrPhotonics to work together in furtherance of its operational objectives. Additional factors that could cause actual results to differ are discussed under the heading "Risk Factors" and in other sections of the GigOptix' filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to GigOptix as of the date hereof, and GigOptix assumes no obligation to update any forward-looking statement.
Source: GigOptix, Inc.
Media:
GigOptix, Inc.
Dr. Josh Nakaska, 408-522-3172
Marketing Director
jnakaska@gigoptix.com
or
Investor Relations:
Darrow Associates, Inc.
Jim Fanucchi, 408-404-5400
ir@gigoptix.com
GIG: Earnings ESP of +25.00% and a Zacks Rank #2.
http://www.zacks.com/stock/news/122728/can-generac-holdings-gnrc-keep-the-earnings-streak-alive
GIG:Analysts' Ratings History for Gigoptix (NYSE:GIG)
12/17/2013 B. Riley Initiated Coverage Buy
11/25/2013 Craig Hallum Initiated Coverage Buy
11/25/2013 Roth Capital Initiated Coverage Buy
http://www.analystratings.net/stocks/NYSE/GIG/
GIG:Exp Earnings Date 2/11/2014.The chart in good standing!
http://stockcharts.com/h-sc/ui?s=GIG&p=D&yr=0&mn=4&dy=0&id=p36279283118
ZN: ZACKS:Exp Earnings Date 2/11/2014
ZN: AMERICAN BULLS: BUY!!
Market Outlook
Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=ZN
IMUC: Phase three is the most difficult, because it is the stage in humans. It may take months, or also negative. We all know the billions spent by companies in this damn disease and most bounce in phase three.
It's how the article says. You have to be positive, but also realistic.
On the other hand there is a point in the chart that must come down.
In my opinion tend to return to their levels of nearly $ 0.75 x share, to correct this glitch.
Regards.
Zion Oil & Gas Update
Friday, January 31, 2014
Dear Shareholder and/or Friend of Zion:
This is an update of noteworthy events that have occurred since our last newsletter. In between updates, please consult our website, press releases, and our SEC filings to keep up with company developments.
Priority and Focus Now on Megiddo-Jezreel License Exploration
In our last update, we informed you that Israel’s Petroleum Commissioner awarded Zion the Megiddo-Jezreel Petroleum Exploration License in December 2013. The License area is about 400 square kilometers or 98,842 acres. Our primary focus is now in this new area that appears to have all of the geologic ingredients of an active petroleum system with good potential.
We continue to work with Geomage, an Israel-based geophysical company, to reprocess existing seismic lines in an effort to improve our subsurface imaging ability in the Megiddo-Jezreel and nearby Jordan Valley License areas. This effort will aid us in high-grading exploration leads to develop them into drillable prospects. We have almost completed reprocessing the first six seismic lines (86 kilometers) and this week instructed Geomage to reprocess another six lines (82 kilometers) for a total of 12 lines (168 kilometers). We are also working with our Israel exploration staff to identify locations to acquire brand new seismic data in conjunction with the Geophysical Institute of Israel. [Click here for an example.]
Elijah #3 Operations
Our original plans to re-enter the Elijah #3 well were delayed primarily due to problems that Lapidoth, our drilling contractor, experienced while drilling another well for a third party. In early January 2014, we initiated re-entry operations and the Lapidoth rig has now been released. Although we had hoped to encounter producible hydrocarbons, we did not (other than minimal amounts of gas) and we will now work to finalize all remaining plugging and abandonment procedures for that well. (Proverbs 24:16a)
Latino Leaders Magazine Article
Zion’s President recently appeared in a special section entitled Latinos in Energy, highlighting how key Latinos are shaping the Energy Industry. Click the following link to read the articles in detail: LatinoLeaders.com
Our Annual Shareholder Meeting will be held on Monday, June 9, 2014 in Caesarea, Israel.
“A man’s heart plans his way, But the Lord directs his steps.”
Proverbs 16:9
Victor G. Carrillo
President and COO
http://www.zionoil.com/updates/zion-oil-gas-update-friday-january-31-2014
Who owns Zion Oil & Gas?
http://stockzoa.com/ticker/zn/
VERY INTERESTING!!!!!
REGARDS.
ZN:Directory of Public Companies in Industry: Oil & Gas Operations
http://www.crmz.com/Directory/Industry609.htm
N°2266
http://www.crmz.com/Directory/Industry609.htm
http://www.crmz.com/Report/ReportPreview.asp?BusinessId=8454217
ZN:THE CHART IN PERFECT POSITION FOR UP!!RSI(14)40.62
P:$1.62
R1:$1.82
R2:$1.2.21
TO FLY!
http://stockcharts.com/h-sc/ui?s=ZN&p=D&yr=0&mn=4&dy=0&id=p36279283118
For everyone's sake, I hope it is so!
But I worry about something that bothers on the chart
Is the CMF(20)0.311
Es muy alta. El resto está muy bien, pero este nivel tiene que bajar. Los vendedores cortos pueden aprovechar esa grieta a caer por debajo de 1,00 dólares
Look the chart, please!
http://stockcharts.com/freecharts/gallery.html?s=IMUC
Please do not lie! That report is VestorVest IMUC
VectorVest
IMUC is overvalued compared to its Price of $1.19 per share, has below average safety, and is currently rated a Sell.
Please do not reply to this email. For answers to your questions, please call 1-888-658-7638, or email us at support@vectorvest.com.
Copyright 2010 by VectorVest, Inc. All Rights Reserved.
20472 Chartwell Center Drive, Cornelius NC 28031
For additional information, call 1-888-658-7638, e-mail to support@vectorvest.com,
or visit our internet site at http://www.vectorvest.com
IMUC - VectorVest Stock Analysis
Company Information
Business: ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.
Capital Appreciation
Value: Value is a measure of a stock's current worth. IMUC has a current Value of $0.39 per share. Therefore, it is overvalued compared to its Price of $1.19 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.
RV (Relative Value): RV is an indicator of long-term price appreciation potential. IMUC has an RV of 0.39, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
RS (Relative Safety): RS is an indicator of risk. IMUC has an RS rating of 0.59, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. IMUC has a Relative Timing rating of 0.22, which is very poor on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.
VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. IMUC has a VST rating of 0.42, which is very poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price.
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. IMUC has a Sell recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.
Tip of the Iceberg
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. IMUC has a Stop of $1.55 per share. This is $0.36 above below IMUC's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. IMUC has a forecasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, as shown weekly in our investment climate report.
EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. IMUC has a forecasted EPS of $-0.28 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. IMUC has a P/E of -4.25. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 40.36. P/E is computed daily using the formula: P/E = Price/EPS.
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. IMUC has an EY of -23.53 percent. This is below the current average of 2.47% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. IMUC has a GPE rating of -1.65. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 2.98%, the operative GPE ratio is 0.09. Therefore, IMUC may be considered to be overvalued.
Dividend Information
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. IMUC does not pay a dividend.
DY (Dividend Yield): DY reflects dividend per share as a percent of Price. IMUC does not pay a dividend, so it does not have a Dividend Yield rating . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. IMUC does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.
DG (Dividend Growth Rate): Dividend Growth is a forecasted annual growth rate of a company's dividend based on historical dividend payments and dividend predictability. It is a subtle yet important indicator of a company’s financial performance. It also provides some insight into the board’s outlook on the company’s ability to increase earnings. IMUC does not pay a dividend, so it does not have a Dividend Growth rating .
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. IMUC does not pay a dividend, so it does not have a YSG rating which is . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for below current income and long-term growth.
Price-Volume Data
Price: IMUC closed on Thursday, January 30, 2014 at $1.19 per share.
Open:IMUC opened trading at a price of $1.21 per share on Thursday, January 30, 2014.
High: IMUC traded at a High price of $1.23 per share on Thursday, January 30, 2014.
Low: IMUC traded at a Low price of $1.18 per share on Thursday, January 30, 2014.
Close: IMUC closed on Thursday, January 30, 2014 at $1.19 per share. (Close is also called Price in the VectorVest system)
Range: Range reflects the difference between the High and Low prices for the day. IMUC traded with a range of $0.05 per share on Thursday, January 30, 2014.
$ Change: IMUC down 0.02 from the prior day's closing Price.
%PRC: IMUC's Price changed -1.65% from the prior day's closing price.
Volume: IMUC traded 1,315,388 shares on Thursday, January 30, 2014.
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. IMUC has an AvgVol of 3,868,602 shares traded per day.
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals ((Volume - AvgVol) / AvgVol ) * 100. IMUC had a %Vol of -66.00% on Thursday, January 30, 2014
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines.IMUC has a CI rating of 0.24, which is very poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.
Sales / Market Capitalization Information
Sales: IMUC has annual sales of 0
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. IMUC has a Sales Growth of 0.00% per year. This is poor. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.
Sales Per Share (SPS): IMUC has annual sales of $0.00 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.
Price to Sales Ratio (P/S): IMUC has a P/S of 0.00. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
Shares: IMUC has 57,000,000 shares of stock outstanding.
Market Capitalization: IMUC has a Market Capitalization of 67,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
Business Sector: IMUC has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Industry Group: IMUC has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013
Thursday, 30 January 2014 18:27 Reports about comments' content 0 Comments
.
ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013
Reportstack has announced a new market research publication on ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013 which provides data on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from proprietary databases, ImmunoCellular Therapeutics, Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from ImmunoCellular Therapeutics, Ltd. and industry-specific third party sources, put together by team of industry experts.
Scope
- ImmunoCellular Therapeutics, Ltd. - Brief ImmunoCellular Therapeutics, Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ImmunoCellular Therapeutics, Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ImmunoCellular Therapeutics, Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ImmunoCellular Therapeutics, Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate ImmunoCellular Therapeutics, Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ImmunoCellular Therapeutics, Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ImmunoCellular Therapeutics, Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ImmunoCellular Therapeutics, Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ImmunoCellular Therapeutics, Ltd. and identify potential opportunities in those areas.
To view the table of contents and know more details please visit ImmunoCellular Therapeutics, Ltd. - Product Pipeline Review - 2013.
NEWS IN GOOGLE FINANCE: Google isn’t the only company working on artificial intelligence. It’s just the richest
http://gigaom.com/2014/01/29/google-isnt-the-only-company-working-on-artificial-intelligence-its-just-the-richest/
Se necesita paciencia, cuando el río hace ruido, porque piedras trae
IMUC valuation if it gets Phase III approval
It's good to have a valuation model that both explains past price behavior as well as give you an idea about the odds that the market is putting on future events.
Here's mine for IMUC.
$500 million revenue potential in US
$500 million revenue potential in Europe
To be conservative, cut that in half.
Company with $500 million revenue at 15% net margin would have $75 million net income.
Valued at a 15x's PE, company worth about $1 billion
Oncology compounds in Phase III have 34% chance of getting FDA approval.
(Source: Internal Medicine News, "Cancer Drugs have worst Phase III track record)
Therefore company worth about $340 MM in Phase III.
If IMUC needs to raise $70 million for Phase III trial (I think I have seen estimates from $60-80MM), pre-money valuation of company if it gets approval for Phase III is worth $270MM ($340 - 70) or 3.85x's current price
IMUC at $1.20 is currently worth $70MM.
So if Phase III approved, stock should move to $4 - $5 range.
Or at $1.20, the market is saying IMUC has a 74% chance of going to zero, and a 26% chance of getting Phase III approval and going to $4.62.
If you use this model, then you are a buyer at $1.20 if you think their odds of getting Phase III approval are better than 26%. Less
IMUC: CLOSE $1.23. First Candle positive. Good indication for tomorrow
Stocks Price Alert:ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC),
By WallStreetAnalyzed · January 28, 2014 · No comments
Press Releases · Tagged: (NASDAQ:CECO), (NYSEMKT:GSS), Career Education Corp., Career Education Corp. (NASDAQ:CECO), Golden Star Resources Ltd. (USA), Golden Star Resources Ltd. (USA) (NYSEMKT:GSS), ImmunoCellular Therapeutics Ltd, ImmunoCellular Therapeutics Ltd. (NYSEMKT:IMUC), NYSEMKT:IMUC
Northern, WI 01/28/2013 (NISMAGAZINE) – Shares of ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) opened at $1.26 and after plunging by 3.17% it closed at $1.22. The intraday range of the stock was $1.22 – $1.29, while its 52-week trading range is of $0.65 and $4.00. At its previous closing, the stock was down by 69.50% from its 52-week high and up by 87.69% from its 52-week low. The company traded with approximately, 3.10 million shares during the session. And its average trading volume remained 5.17 million shares. The company has market capitalization of $69.66 million with 57.10 million shares outstanding. The company is engaged in development and marketing of immune-based therapies which is useful in the treatment of ovarian, brain, and other solid tumors.
Is IMUC a solid investment at these levels? Find out here.
http://www.nismagazine.com/stocks-price-alertimmunocellular-therapeutics-ltd-nysemktimuc-golden-star-resources-ltd-usa-nysemktgss-career-education-corp-nasdaqceco/1217371/
IMUC: THE CHART, Possible recovery, how you say
http://stockcharts.com/h-sc/ui?s=IMUC&p=D&yr=0&mn=4&dy=0&id=p36279283118
IMUC,IN GOOGLE FINANCE:Therapeutics Ltd (NYSEMKT:IMUC) showed a volume of 3.60 million shares by the end of last trade whereas the average volume of the stock remained 5.17 million shares. The stock opened the session at $1.34but then moved to $1.26. At that price, the stock showed a negative performance of -5.97%. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.
Will IMUC Get Buyers Even After The Recent Rally? Find Out Here
http://www.sbwire.com/press-releases/traders-buzzers-immunocellular-therapeutics-ltd-nysemktimuc-aeropostale-inc-nysearo-mcewen-mining-inc-nysemuxchelsea-therapeutics-international-ltd-nasdaqchtp-447666.htm
SEEKING ALPHA:Focus On Cancer Immunotherapy Results.
Jan. 25, 2014 3:41 AM ET | 4 comments | About: IMUC, Includes: AGEN, BMY, MRK, NWBO
Disclosure: I am long IMUC. (More...)
Recently, ImmunoCellular Therapeutics Ltd. (NYSE: IMUC) announced the midterm phase II results of their flagship drug ICT-107 showing a median overall survival increase of 2.0 months vs. the company previously hoped for 9 month expected benefit - a conservative bet from the much larger number (23.8 improvement over standard of care) in its phase I trial. This was disappointing to investors who struggle to assess the meaning of the results. Despite this, a few things should be considered for this area, but it should also be understood that cancer immunotherapy or "Immuno-oncology" is here to stay and has become a prioritized area of research and development all the way from large Pharma to the early stage companies who are really responsible for the major innovative push in this area. There has been a continuous effort to develop cancer immunotherapy for decades and it is safe to say that recent key developments and newly acquired knowledge now make immunotherapy a reality as a new drug class. With that said, from the investors' point of view, the questions to ask is what form it will take and who will emerge as winners in the field. For those investing in this area, there are financial, technical and market risks, but it goes without saying that the technical risks are emphasized in this area. It is hard to know how well the different technical approaches will work until they do.
Technical: ICT-107 is based upon 6 tumor markers (antigens) commonly found on tumors and it is believed that by pre-selecting known markers, especially if you choose more than one, you will be deploying sound scientific body of knowledge and data to redirect the immune system against the tumor. This is in contrast to the tumor lysate approach used by Northwest Biotherapeutics (NWBO) with DCVax®-L where sections of the tumor are ground up and whatever is targeted by the immune system is targeted (what is most immunogenic and/ or most present), with the hope that such markers are important for tumor growth (some may or may not be). See previous summary of the different approaches to cancer vaccines and immunotherapy in this area. In the end, we would love to predict the future but the emerging data will provide a good hint as to which approach is better, no matter how much words are said about it. Having been in the field long enough, data tends to surprise us. It is true that phase I data in many cases is better than phase II data or even phase III data for multiple reasons already discussed, but this was accounted for by IMUC in their hope for a fraction of the phase I results as mentioned above. The truth is, the drug did work but just not as well as hoped for. It was accurately stated that ICT-107 could get approved even with the current numbers.
The decision to proceed from phase II to phase III trials in oncology is more challenging today because of the increasing awareness of the complexity and molecular heterogeneity of tumors; even ones that originate from the same primary site. In addition, drugs typically have been focused to target specific cellular pathways and metastatic sites, but now there is an emerging context for more personalized treatment planning. DCVax®-L appears to have a more personalized approach and therefore, its upcoming release of data will be important to assess the best approach in this race. Agenus (NASDAQ: AGEN), which also relies on using highly personalized treatment in its vaccine by extracting peptides from the tumor with its gp96 dependent Prophage Series G-200 drug recently announced a median overall survival of approximately eleven months in phase II on GBM. In any case, it should also be mentioned that phase II is designed to learn and better design a phase III unless otherwise stated. It is possible IMUC may take notice to biomarkers that correlate with drug efficacy that may improve statistics in the next trial if they collected such information and focus on that population, much as the Herceptin (Genentech/Roche) case. For example, if they checked the tumor for the very markers they target. This is in fact what was indicated in their Form 8-K release last week.
Financial: I think there were some valid concerns addressed by Smith in his article regarding the ability to finance a phase III study and possibly competing to recruit similar patients. According to their Form-10Q, they have total assets of $29,939,033 (as of 9/30/2013) with a recent burn rate of approximately $3 million +/quarter with no outstanding debt. Remaining shares 57.1 million. It is true that they will not know how many patients they will need to enroll if they wish to advance to phase III trials, however, the smaller the delta (difference in treated and non-treated) this may require more numbers and incur larger costs. Even so, I am less concerned about the ability to finance the trials as long as the data remains promising for approval. It is true that at a cost of ~$100,000 per patient at 600 patients, the phase III trial would cost $60 million. However, if the drug is good and no debts incurred for the company, there are several possible avenues to raise the remaining capital through 2018. If there was significant debt, this would be a more challenging possibility.
In addition to what has already been said by others, it is possible that the introduction of ICT-140 for ovarian cancer and ICT-121 targeting cancer stem cells in GBM will likely renew interest in the battered stock. In fact the stock has risen significantly from the introduction of this candidates. IMUC also has a very strong patent portfolio for the dendritic approach and this will serve them in creating value, a point that is often overlooked by investors because it is not as visible. This could be a determining factor in an acquisition if phase III shows promising results, or the other candidates, and if this is a desired strategy for the company. With all that said, the main point is, there are alternate ways to create value for investors if they take advantage of them but above all, they need to demonstrate the technology works and the approach is competitive, hence, I assess that the biggest risk is technical.
Market: One of the most significant factors to be understood is a reality check on what is trying to be attempted here. Market decisions are made when a development campaign is initiated for cancers that are common for larger populations and those cancers are drugable, which include examples like prostate, breast, hematopoietic (Leukemia, Lymphoma), thyroid cancers etc. It is safe to say that most of these programs are mature but regulatory agencies are providing incentives, such as orphan status which provides significant financial upsides on exclusivity as well as development money (IMUC is seeking orphan drug grant funds which can be tens of millions of dollars) to pursue these much harder and smaller market targets. The point here is that with GBM, much like ovarian and other select group of cancers, most people do not live long and much of what we have thrown at it over the decades has not worked. Thus, for the current standard of care, temozolomide (Merck (NYSE:MRK), approved in its phase III (575 participants randomized to standard radiation versus radiation plus temozolomide chemotherapy), showed that the group receiving temozolomide survived a median of 14.6 months as opposed to 12.1 months for the group receiving radiation alone which is just barely over 2 months: See New England Journal of Medicine 352 (10): 987-96.
A second factor is that the future that these drugs are being developed into is changing rapidly. It is likely that the checkpoint inhibitors being developed such as Bristol-Myers Squibb's (NYSE:BMY) anti-CTLA-4 Yervoy (ipilumumab) (Approved 2011) along with anti-PD-1 monoclonal antibodies (mAbs) from Merck , BMS and Roche (OTCQX:RHHBY), not to mention recent targets such as TIM-3, will be used in combination with the dendritic or other immunotherapy drugs. This of course would need separate trials but mechanistically it makes sense; one redirects the immune system to attack cancer and the other prevents the local suppression of the immune by the tumor, the combination of which may impact survival statistics much greater.
In summary, the risk weighs most heavily on the technical area for IMUC, but this is also true for the others in the field at this point. The lack of toxicity for a dendritic base immunotherapy and low cost is a huge upside for this area where patients are making decisions on quality of the remaining months they have vs. doing further harm with highly toxic chemotherapeutic chemical drugs. However, their burden will be to demonstrate that the product works and is competitive with existing therapeutics or complementary to them when deployed in a treatment plan.
This article was sent to 4,817 people who get email alerts on IMUC.
Get email alerts on IMUC »
http://seekingalpha.com/article/1967341-focus-on-cancer-immunotherapy-results?source=yahoo
Notice in Yahoo Finance:NeoStem’s AMR-001 Has Strong Chance of Success
http://wallstcheatsheet.com/stocks/neostems-amr-001-has-strong-chance-of-success.html/?ref=YF
IMUC:Analyst Ratings. TARGET:$7.00
http://www.streetinsider.com/rating_history.php?q=IMUC
IMUC:NASDAQ:Analyst Recommendations STRONG BUY
http://www.nasdaq.com/symbol/imuc/recommendations
IMUC:AMERICAN BULL, CHART:STAY LONG
http://www.americanbulls.com/SignalPage.aspx?lang=en&Ticker=IMUC
IMUC:CHART:P:$1.67 R1:$2.68 R2:$4.43 FLY!!!!
http://stockcharts.com/h-sc/ui?s=IMUC&p=D&yr=0&mn=4&dy=0&id=p36279283118
IMUC:FINANCIAL TIME: ANALYSIS & PROJECTION. SHORT SELLING: LOW
http://markets.ft.com/research/Markets/Tearsheets/Summary?s=IMUC:ASQ
The Chart 2
http://stockcharts.com/freecharts/gallery.html?s=IMUC
UP; UP; UP!!!!!!!!!!!!!!!!!!!!!!
IMUC: CHART NEWS, BUY!!!!!
http://stockcharts.com/h-sc/ui?s=IMUC&p=D&b=5&g=0&id=p26099102557&a=264845671
IMUC: THE CHART, FLY, BUY!!!!
http://stockcharts.com/h-sc/ui
I love your positive attitude with ASYI how inverter.
Positive mental attitude, a way to success !!! Go ASYI !!!
Regards.
TDA, not because he wanted to put it. I spoke and told me that it is the company that warns and says he is not responsible for operations from DTC CHILL notice.
You can call and ask, as I did . Is the company warns, is because exist.
Logic conclucion of ASYI.
ASYI: That may indicate that there are fewer shares in the float, that means that when the day closes with only 100 shares on the ask, its value increases.
ASYI: It's the first time I see the ASK to $8.00 in TDA
2,051,556,444 shares, in the 2013. They bought? sold? or AISystems Inc. repurchased?
$2,051,556.444. It is a lot of money! no? jejeje
I think, that before data review by AISystems Inc, have to find out, call and check. If it is true, very good news.
To try. It should be positive
Chairman of the Advisory Board:Salman Ullah Ph.D.
http://investing.businessweek.com/research/stocks/private/person.asp?personId=1525436&privcapId=40273995&previousCapId=47527472&previousTitle=AISYSTEMS%20INC
Other Board Members on Board: Update 1/10/14
http://investing.businessweek.com/research/stocks/people/board.asp?ticker=ASYI
New Market Research Report: AISystems, Inc. (ASYI) - Financial and Strategic SWOT Analysis Review
2014-01-08 10:16:33 - Fast Market Research recommends "AISystems, Inc. (ASYI) - Financial and Strategic SWOT Analysis Review" from GlobalData, now available
This comprehensive SWOT profile of AISystems, Inc. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData's 'Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of AISystems, Inc. including a detailed SWOT analysis, and deliver this direct
http://reports.pr-inside.com/new-market-research-report-aisystems-inc-r3895954.htm